Cargando…
A Prospective, Phase I/II, Open-Label Pilot Trial to Assess the Safety of Hyperthermic Intraperitoneal Chemotherapy After Oncological Resection of Pancreatic Adenocarcinoma
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a common fatal disease with unfavorable prognosis, even after oncological resection. To improve survival, adding hyperthermic intraperitoneal chemotherapy (HIPEC) has been suggested. Whether HIPEC entails disproportional short-term mortality is...
Autores principales: | Yurttas, Can, Horvath, Philipp, Fischer, Imma, Meisner, Christoph, Nadalin, Silvio, Königsrainer, Ingmar, Königsrainer, Alfred, Beckert, Stefan, Löffler, Markus W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205203/ https://www.ncbi.nlm.nih.gov/pubmed/34131821 http://dx.doi.org/10.1245/s10434-021-10187-8 |
Ejemplares similares
-
In-Hospital Mortality and Complication Rates According to Health Insurance Data in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies in Germany
por: Überrück, Lisa, et al.
Publicado: (2020) -
Reply to: “Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Definitively Does Not Deserve Its Bad Reputation”
por: Horvath, Philipp, et al.
Publicado: (2021) -
Predicting Early and Late Readmissions Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
por: Moon, Eui Whan, et al.
Publicado: (2021) -
Coagulopathy and Venous Thromboembolic Events Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
por: Dranichnikov, Paul, et al.
Publicado: (2021) -
Surgeons’ Ability to Predict the Extent of Surgery Prior to Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
por: Hentzen, Judith E. K. R., et al.
Publicado: (2020)